Tracking factor X deficiency to improve patient care
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This study collects health information and blood samples from people with factor X deficiency (a rare bleeding disorder) and their close family members. The goal is to learn more about how the condition progresses over time, which could lead to better treatment and management.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with factor X deficiency (low levels of the factor X protein in your blood).
- You are willing to provide blood samples and health information.
- You are willing to participate in follow-up visits for this study.
- You do not have other clotting factor deficiencies (besides factor X).
- You have not had an organ transplant.
- If you are a family member of someone with factor X deficiency, you may also qualify.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at why the body sometimes stops responding to factor VIII treatment in hemophilia A. It aims to find patterns that help doctors predict and manage this, so they can keep the treatment working well.
This trial tests a new medicine called CITY-FXI to see if it is safe and well tolerated in people who are at higher risk of blood clots, including those with certain genetic mutations or a past blood clot. It helps doctors find the right dose for future studies.
This trial tests a drug called VMX-C001 to quickly reverse the effects of certain blood thinners (Factor Xa inhibitors) in people who need urgent surgery with a high risk of bleeding. It compares VMX-C001 to standard care to see which is more effective at helping blood clot normally.
This study observes patients with blood clotting or bleeding disorders over time to collect health information and improve care.
This study tests how well and how safely Octapharma’s clotting factor products (Nuwiq, Octanate, or Wilate) work in people with Hemophilia A who are newly treated or have had very few clotting factor doses. It also looks at how often side effects occur and how the treatments are used in real care.
This study follows people with inherited or acquired non-cancer blood disorders to better understand symptoms, causes, and how different treatments work over time. You may be placed into a disorder-specific group, depending on your diagnosis and testing results.
Hear when a new Factor X Deficiency trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.